SecBot SecBot
DEFA14A ·Filed Jun 22, 2026

PHGE

BiomX Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001213900-26-070669
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for a subsequent 8-K announcing the appointment of an auditor for FY2026. The lack of an appointed auditor four days before the annual meeting is a minor governance concern but not yet a material red flag. No trading action warranted based on this filing alone.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.4615
T+0 close · Jun 22, 2026 · via day close
Latest settled
−56.66%
T+20 · $0.2000
Vs SPY
−57.82%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 23 $0.4615entry
  2. T+1 · 5mo ago −9.75%α −9.70% · $0.4165
  3. T+5 · 5mo ago −22.21%α −23.22% · $0.3590
  4. T+20 · 4mo ago −56.66%α −57.82% · $0.2000
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. filed a DEFA14A supplement correcting an error in its proxy statement: the Audit Committee did not appoint Kesselman & Kesselman (PwC Israel) as auditor for FY2026, contrary to the original statement. The company has not yet selected an auditor for FY2026, and the annual meeting proposals remain unchanged.

Key Financial Metrics

Meeting
2026-06-26

Key Facts

  • Correction: original proxy statement erroneously stated Kesselman & Kesselman was appointed as auditor for FY2026; no appointment has been made.
  • Audit Committee is in the process of selecting an independent registered public accounting firm for FY2026.
  • Annual meeting scheduled for June 26, 2026; proposals unchanged (director election, equity plan amendment, adjournment).
  • Prior auditor Kesselman & Kesselman served for FY2024 and FY2025 and audited the FY2025 10-K.

Financial Impact

No direct financial impact; potential indirect risk if auditor appointment is delayed, but no material exposure quantified.

Risk Factors

  • Delay in auditor appointment could lead to late filing of the FY2026 10-K if not resolved promptly.
  • Correction highlights potential internal control or disclosure weaknesses at a micro-cap company.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-070669
Document: 0001213900-26-070669-index-headers.html0001213900-26-070669
Document: 0001213900-26-070669-index.html0001213900-26-070669
Document: 0001213900-26-070669.txt0001213900-26-070669

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026